Anti-EGFR-targeted therapy for esophageal and gastric cancers: An evolving concept

Journal of Oncology

Volumn , Issue , 2009, Pages

  Dragovich, Tomislav ^a   Campen, Christopher ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; LAPATINIB; NAVELBINE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; HUMAN; LOWER ESOPHAGUS SPHINCTER; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

EID: 68949109786     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/804108     Document Type: Review

References (59)

1. Jemal A., Siegel R., Ward E., Cancer statistics, 2008 CA: Cancer Journal for Clinicians 2008 58 2 71 96
2. Parkin D. M., Bray F., Ferlay J., Pisani P., Estimating the world cancer burden: Globocan 2000 International Journal of Cancer 2001 94 2 153 156 (Pubitemid 32911406)
3. Ohtsu A., Chemotherapy for metastatic gastric cancer: past, present, and future Journal of Gastroenterology 2008 43 4 256 264
4. Blot W. J., McLaughlin J. K., The changing epidemiology of esophageal cancer Seminars in Oncology 1999 26 5, supplement 15 2 8
5. Lagergren J., Bergstrm R., Lindgren A., Nyrn O., Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma The New England Journal of Medicine 1999 340 11 825 831
6. Enzinger P. C., Mayer R. J., Esophageal cancer The New England Journal of Medicine 2003 349 23 2241 2252
7. Correa P., Fox J., Fontham E., Helicobacter pylori and gastric carcinoma. Serum antibody prevalence in populations with contrasting cancer risks Cancer 1990 66 12 2569 2574
8. Ferry D. R., Anderson M., Beddard K., A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response Clinical Cancer Research 2007 13 19 5869 5875
9. Janmaat M. L., Gallegos-Ruiz M. I., Rodriguez J. A., Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients Journal of Clinical Oncology 2006 24 10 1612 1619
10. Dragovich T., McCoy S., Fenoglio-Preiser C. M., Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127 Journal of Clinical Oncology 2006 24 30 4922 4927
11. Hecht J. R., Urba S. G., Koehler M., Lapatinib monotherapy in recurrent gastrointestinal malignancy: phase II efficacy and biomarker analyses Proceedings of the American Society of Clinical Oncology, Gastrointestinal Cancers Symposium 2008. abstract no. 43
12. Oncology drugs approved by the FDA. December 2008, http://www. centerwatch.com/patient/drugs/area12.html
13. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer Cancer Biology Therapy 2006 5 4 340 342
14. Giusti R. M., Shastri K. A., Cohen M. H., Keegan P., Pazdur R., FDA drug approval summary: panitumumab (Vectibix TM) Oncologist 2007 12 5 577 583
15. Cohen M. H., Johnson J. R., Chen Y.-F., Sridhara R., Pazdur R., FDA drug approval summary: erlotinib (Tarceva ) tablets Oncologist 2005 10 7 461 466
16. Laurent-Puig P., Taieb J., Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer? Current Opinion in Oncology 2008 20 4 454 458
17. Karamouzis M. V., Grandis J. R., Argiris A., Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas Journal of the American Medical Association 2007 298 1 70 82
18. Ciardiello F., Tortora G., EGFR antagonists in cancer treatment The New England Journal of Medicine 2008 358 11 1160 1174
19. Hynes N. E., Lane H. A., ERBB receptors and cancer: the complexity of targeted inhibitors Nature Reviews Cancer 2005 5 5 341 354
20. Hynes N. E., Lane H. A., Erratum: ERBB receptors and cancer: the complexity of targeted inhibitors Nature Reviews Cancer 2005 5 7 580
21. Gold P. J., Goldman B., Iqbal S., Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group Study Proceedings of the American Society of Clinical Oncology Annual Meeting 2008. abstract no. 4536
22. Ku G. Y., Shah M. A., Tang L. H., Cetuximab (C225) plus irinotecan/cisplatin (CPT/Cis) for CPT/Cis-refractory esophageal cancer Proceedings of the American Society of Clinical Oncology Annual Meeting 2008. abstract no. 15580
23. Pinto C., Di Fabio F., Siena S., Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) Annals of Oncology 2007 18 3 510 517
24. Han S.-W., Oh D.-Y., Im S.-A., Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer British Journal of Cancer 2009 100 2 298 304
25. Imai K., Takaoka A., Comparing antibody and small-molecule therapies for cancer Nature Reviews Cancer 2006 6 9 714 727
26. Baselga J., Pfister D., Cooper M. R., Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin Journal of Clinical Oncology 2000 18 4 904 914
27. Tabernero J., Pfeiffer P., Cervantes A., Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? The Oncologist 2008 13 2 113 119
28. Lacouture M. E., Mechanisms of cutaneous toxicities to EGFR inhibitors Nature Reviews Cancer 2006 6 10 803 812
29. Saltz L., Rubin M. S., Hochster H., Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) pluls irinotecan (CPT-11) in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) Clinical Cancer Research 2001 7 3766s. abstract no. 559
30. Wacker B., Nagrani T., Weinberg J., Witt K., Clark G., Cagnoni P. J., Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies Clinical Cancer Research 2007 13 13 3913 3921
31. Soulieres D., Senzer N. N., Vokes E. E., Hidalgo M., Agarvala S. S., Siu L. L., Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck Journal of Clinical Oncology 2004 22 1 77 85
32. Gordon A. N., Finkler N., Edwards R. P., Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study International Journal of Gynecological Cancer 2005 15 5 785 792
33. Tejpar S., Peeters M., Humblet Y., Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data Journal of Clinical Oncology 2007 25 18, supplement. abstract no. 4037
34. Enzinger P. C., Mayer R. J., Esophageal cancer The New England Journal of Medicine 2003 349 23 2241 2252
35. Bleiberg H., Conroy T., Paillot B., Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer European Journal of Cancer 1997 33 8 1216 1220
36. Ilson D. H., Ajani J., Bhalla K., Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus Journal of Clinical Oncology 1998 16 5 1826 1834
37. Ilson D. H., Forastiere A., Arquette M., A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus Cancer Journal 2000 6 5 316 323
38. Petrasch S., Welt A., Reinacher A., Graeven U., Knig M., Schmiegel W., Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer British Journal of Cancer 1998 78 4 511 514
39. Ilson D. H., Saltz L., Enzinger P., Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer Journal of Clinical Oncology 1999 17 10 3270 3275
40. Kok T. C., van der Gaast A., Dees J., Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group British Journal of Cancer 1996 74 6 980 984
41. Shah M. A., Schwartz G. K., Treatment of metastatic esophagus and gastric cancer Seminars in Oncology 2004 31 4 574 587
42. Webb A., Cunningham D., Scarffe J. H., Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer Journal of Clinical Oncology 1997 15 1 261 267
43. van Cutsem E., Moiseyenko V. M., Tjulandin S., Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V25 Study Group Journal of Clinical Oncology 2006 24 31 4991 4997
44. Ajani J. A., Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen Cancer 2008 113 5 945 955
45. Cunningham D., Starling N., Rao S., Capecitabine and oxaliplatin for advanced esophagogastric cancer The New England Journal of Medicine 2008 358 1 36 46
46. Seo M.-D., Lee K.-W., Lim J. H., Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer Japanese Journal of Clinical Oncology 2008 38 9 589 595
47. Oh S. Y., Kwon H.-C., Seo B.-G., Kim S.-H., Kim J.-S., Kim H.-J., A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer Acta Oncologica 2007 46 3 336 341
48. Ajani J. A., Lee F.-C., Singh D. A., Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma Journal of Clinical Oncology 2006 24 4 663 667
49. Toker A., Yoeli-Lerner M., Akt signaling and cancer: surviving but not moving on Cancer Research 2006 66 8 3963 3966
50. Roberts P. J., Der C. J., Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 2007 26 22 3291 3310
51. Meloche S., Pouyssegur J., The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition Oncogene 2007 26 22 3227 3239
52. Takaoka M., Harada H., Andl C. D., Epidermal growth factor receptor regulates aberrant expression of insulin-like growth factor-binding protein 3 Cancer Research 2004 64 21 7711 7723
53. Al-Kasspooles M., Moore J. H., Orringer M. B., Beer D. G., Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas International Journal of Cancer 1993 54 2 213 219
54. Rygiel A. M., Milano F., Ten Kate F. J., Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of barretts esophagus Cancer Epidemiology Biomarkers Prevention 2008 17 6 1380 1385
55. Miller C. T., Moy J. R., Lin L., Gene amplification in esophageal adenocarcinomas and barretts with high-grade dysplasia Clinical Cancer Research 2003 9 13 4819 4825
56. Nicholson R. I., Gee J. M. W., Harper M. E., EGFR and cancer prognosis European Journal of Cancer 2001 37 supplement 4 S9 S15
57. Kim M. A., Lee H. S., Lee H. E., Jeon Y. K., Yang H. K., Kim W. H., EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number Histopathology 2008 52 6 738 746
58. Rojo F., Tabernero J., Albanell J., Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma Journal of Clinical Oncology 2006 24 26 4309 4316
59. Baker A. F., Dragovich T., Ihle N. T., Williams R., Fenoglio-Preiser C., Powis G., Stability of phosphoprotein as a biological marker of tumor signaling Clinical Cancer Research 2005 11 12 4338 4340